Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Shaughnessy

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
British Journal of Haematology|April 17, 2004
The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cellsKarin Tarte, Michel Jourdan, Jean Luc Veyrune, et al.
Best Practice & Research. Clinical Haematology|December 12, 2007
The Arkansas approach to therapy of patients with multiple myelomaBart Barlogie, Elias Anaissie, Frits van Rhee, et al.
Blood|May 12, 2005
Wnts induce migration and invasion of myeloma plasma cellsYa-Wei Qiang, Katie Walsh, Lei Yao, et al.
Molecular Cancer Therapeutics|March 1, 2006
IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cellsNaoko Takebe, Xiangfei Cheng, Tamer E Fandy, et al.
JAMA Network Open|August 26, 2022
Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple MyelomaRaghad Alqazaqi, Carolina Schinke, Sharmilan Thanendrarajan, et al.
Cell Division|October 20, 2006
Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expressionAmel Dib, Timothy R Peterson, Laura Raducha-Grace, et al.
British Journal of Haematology|July 25, 2003
MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplantsJoth Jacobson, Bart Barlogie, John Shaughnessy, et al.
Cytotherapy|December 22, 2010
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103Amberly Moreno-Bost, Susann Szmania, Katie Stone, et al.
British Journal of Haematology|September 12, 2009
Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 ampliconJeffrey R Sawyer, Erming Tian, Edward Thomas, et al.
Hematology. American Society of Hematology. Education Program|November 25, 2003
Advances in biology and therapy of multiple myelomaSophie Barillé-Nion, Bart Barlogie, Régis Bataille, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
British Journal of Haematology|April 17, 2004
The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cellsKarin Tarte, Michel Jourdan, Jean Luc Veyrune, et al.
Best Practice & Research. Clinical Haematology|December 12, 2007
The Arkansas approach to therapy of patients with multiple myelomaBart Barlogie, Elias Anaissie, Frits van Rhee, et al.
Blood|May 12, 2005
Wnts induce migration and invasion of myeloma plasma cellsYa-Wei Qiang, Katie Walsh, Lei Yao, et al.
Molecular Cancer Therapeutics|March 1, 2006
IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cellsNaoko Takebe, Xiangfei Cheng, Tamer E Fandy, et al.
JAMA Network Open|August 26, 2022
Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple MyelomaRaghad Alqazaqi, Carolina Schinke, Sharmilan Thanendrarajan, et al.
Cell Division|October 20, 2006
Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expressionAmel Dib, Timothy R Peterson, Laura Raducha-Grace, et al.
British Journal of Haematology|July 25, 2003
MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplantsJoth Jacobson, Bart Barlogie, John Shaughnessy, et al.
Cytotherapy|December 22, 2010
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103Amberly Moreno-Bost, Susann Szmania, Katie Stone, et al.
British Journal of Haematology|September 12, 2009
Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 ampliconJeffrey R Sawyer, Erming Tian, Edward Thomas, et al.
Hematology. American Society of Hematology. Education Program|November 25, 2003
Advances in biology and therapy of multiple myelomaSophie Barillé-Nion, Bart Barlogie, Régis Bataille, et al.
Pageof 6